Login / Signup
Reply: Aspirin and GLP-1RAs-The missing confounders of empagliflozin for MASLD without diabetes mellitus?
Michael Ka-Shing Cheung
Wai-Keung Leung
Published in:
Hepatology (Baltimore, Md.) (2024)
Keyphrases
</>
low dose
wild type
cardiovascular events
antiplatelet therapy
glycemic control
acute coronary syndrome
type diabetes
percutaneous coronary intervention
cardiovascular disease
adipose tissue
metabolic syndrome
atrial fibrillation